Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study.
Lucija KovacevicMarko PetroveckiLea KorsaZlatko MarusicIvo Dumic-CuleMaja PrutkiPublished in: Diagnostics (Basel, Switzerland) (2023)
This study aimed to evaluate the performance of multiparametric breast magnetic resonance imaging (mpMRI) for predicting response to neoadjuvant chemotherapy (NAC) in patients with luminal B subtype breast cancer. The prospective study included thirty-five patients treated with NAC for both early and locally advanced breast cancer of the luminal B subtype at the University Hospital Centre Zagreb between January 2015 and December 2018. All patients underwent breast mpMRI before and after two cycles of NAC. Evaluation of mpMRI examinations included analysis of both morphological (shape, margins, and pattern of enhancement) and kinetic characteristics (initial signal increase and post-initial behavior of the time-signal intensity curve), which were additionally interpreted with a Göttingen score (GS). Histopathological analysis of surgical specimens included grading the tumor response based on the residual cancer burden (RCB) grading system and revealed 29 NAC responders (RCB-0 (pCR), I, II) and 6 NAC non-responders (RCB-III). Changes in GS were compared with RCB classes. A lack of GS decrease after the second cycle of NAC is associated with RCB class and non-responders to NAC.
Keyphrases
- neoadjuvant chemotherapy
- transcription factor
- locally advanced
- magnetic resonance imaging
- rectal cancer
- lymph node
- genome wide analysis
- sentinel lymph node
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- phase ii study
- computed tomography
- newly diagnosed
- ejection fraction
- chronic kidney disease
- early stage
- prognostic factors
- risk factors
- high intensity
- young adults
- magnetic resonance
- contrast enhanced
- breast cancer risk
- study protocol